相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
N. Nishimoto et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment
S. Nishida et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Clinical value of blocking IL-6 receptor
Toru Mima et al.
CURRENT OPINION IN RHEUMATOLOGY (2009)
Targeting interleukin-6 in pediatric rheumatic diseases
Fabrizio De Benedetti
CURRENT OPINION IN RHEUMATOLOGY (2009)
A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years
Hideko Nakahara et al.
MODERN RHEUMATOLOGY (2009)
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
Norihiro Nishimoto et al.
MODERN RHEUMATOLOGY (2009)
Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis
M. Kawai et al.
RHEUMATOLOGY (2009)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2008)
Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody
Norihiro Nishimoto et al.
ARTHRITIS AND RHEUMATISM (2008)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S. Smolen et al.
LANCET (2008)
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial
Shumpei Yokota et al.
LANCET (2008)
TH 17 cells in development:: an updated view of their molecular identity and genetic programming
Chen Dong
NATURE REVIEWS IMMUNOLOGY (2008)
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
Norihiro Nishimoto et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis
Yasuaki Okuda et al.
ARTHRITIS AND RHEUMATISM (2006)
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
R. N. Maini et al.
ARTHRITIS AND RHEUMATISM (2006)
A severe case of chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents
Tomoyo Matsubara et al.
ARTHRITIS AND RHEUMATISM (2006)
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
E Bettelli et al.
NATURE (2006)
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease
N Nishimoto et al.
BLOOD (2005)
Therapeutic Efficacy of Humanized Recombinant Anti-Interleukin-6 Receptor Antibody in Children With Systemic-Onset Juvenile Idiopathic Arthritis
Shumpei Yokota et al.
ARTHRITIS AND RHEUMATISM (2005)
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease
H Ito et al.
GASTROENTEROLOGY (2004)
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody - A multicenter, double-blind, placebo-controlled trial
N Nishimoto et al.
ARTHRITIS AND RHEUMATISM (2004)
Humanized monoclonal anti-interieukin-6 receptor antibody for treatment of intractable adult-onset Still's disease
M Iwamoto et al.
ARTHRITIS AND RHEUMATISM (2002)
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis - A randomized, double-blind, placebo-controlled, dose-escalation trial
EHS Choy et al.
ARTHRITIS AND RHEUMATISM (2002)
A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma
P Moreau et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
分享论文
